@article{Mara M. Epstein_Bernard Rosner_Elizabeth C. Breen_Julie L. Batista_Edward L. Giovannucci_Larry Magpantay_Jon C. Aster_Scott J. Rodig_Kimberly A. Bertrand_Francine Laden_Otoniel Martínez-Maza_Brenda M. Birmann_2018, place={Pavia, Italy}, title={Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies}, volume={103}, url={https://haematologica.org/article/view/8625}, DOI={10.3324/haematol.2017.183236}, abstractNote={Inflammation and B-cell hyperactivation have been associated with non-Hodgkin lymphoma development. This prospective analysis aimed to further elucidate pre-diagnosis plasma immune marker profiles associated with non-Hodgkin lymphoma risk. We identified 598 incident lymphoma cases and 601 matched controls in Nurses’ Health Study and Health Professionals Follow-up Study participants with archived pre-diagnosis plasma samples and measured 13 immune marker levels with multiplexed immunoassays. Using multivariable logistic regression we calculated Odds Ratios (OR) and 95% Confidence Intervals (CI) per standard deviation unit increase in biomarker concentration for risk of non-Hodgkin lymphoma and major histological subtype, stratifying additional models by years (<5, 5 to &lt;10, ≥10) after blood draw. Soluble interleukin-2 receptor-α, CXC chemokine ligand 13, soluble CD30, and soluble tumor necrosis factor receptor-2 were individually positively associated, and B-cell activating factor of the tumor necrosis factor family inversely associated, with all non-Hodgkin lymphoma and one or more subtypes. The biomarker combinations associated independently with lymphoma varied somewhat by subtype and years after blood draw. Of note, the unexpected inverse association between B-cell activating factor and chronic lymphocytic leukemia/small lymphocytic lymphoma risk (OR: 95%CI: 0.51, 0.43-0.62) persisted more than ten years after blood draw (OR: 0.70; 95%CI: 0.52-0.93). In conclusion, immune activation precedes non-Hodgkin lymphoma diagnosis by several years. Decreased B-cell activating factor levels may denote nascent chronic lymphocytic leukemia many years pre-diagnosis.}, number={10}, journal={Haematologica}, author={Mara M. Epstein and Bernard Rosner and Elizabeth C. Breen and Julie L. Batista and Edward L. Giovannucci and Larry Magpantay and Jon C. Aster and Scott J. Rodig and Kimberly A. Bertrand and Francine Laden and Otoniel Martínez-Maza and Brenda M. Birmann}, year={2018}, month={Sep.}, pages={1679-1687} }